Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Acquired by Dynamic Technology Lab Private Ltd

Dynamic Technology Lab Private Ltd increased its holdings in shares of Vir Biotechnology, Inc. (NASDAQ:VIR) by 77.2% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 31,900 shares of the company’s stock after acquiring an additional 13,893 shares during the period. Dynamic Technology Lab Private Ltd’s holdings in Vir Biotechnology were worth $239,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Louisiana State Employees Retirement System grew its holdings in Vir Biotechnology by 2.8% in the second quarter. Louisiana State Employees Retirement System now owns 43,800 shares of the company’s stock valued at $390,000 after purchasing an additional 1,200 shares during the period. Blue Trust Inc. lifted its position in shares of Vir Biotechnology by 143.5% during the 3rd quarter. Blue Trust Inc. now owns 3,989 shares of the company’s stock valued at $30,000 after buying an additional 2,351 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Vir Biotechnology by 15.0% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 24,647 shares of the company’s stock valued at $219,000 after buying an additional 3,215 shares in the last quarter. Innealta Capital LLC acquired a new stake in Vir Biotechnology in the 2nd quarter valued at $32,000. Finally, The Manufacturers Life Insurance Company increased its holdings in Vir Biotechnology by 7.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 48,987 shares of the company’s stock worth $436,000 after acquiring an additional 3,605 shares in the last quarter. Hedge funds and other institutional investors own 65.32% of the company’s stock.

Insider Activity at Vir Biotechnology

In related news, Director Janet Napolitano sold 12,190 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $7.80, for a total value of $95,082.00. Following the transaction, the director now directly owns 11,616 shares in the company, valued at approximately $90,604.80. This represents a 51.21 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last quarter, insiders sold 15,940 shares of company stock valued at $127,410. 15.60% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $19.00 price objective on shares of Vir Biotechnology in a report on Wednesday, November 20th. Barclays lowered their price objective on Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. Finally, HC Wainwright reissued a “buy” rating and set a $110.00 target price on shares of Vir Biotechnology in a report on Wednesday, November 20th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Vir Biotechnology currently has an average rating of “Moderate Buy” and a consensus target price of $36.40.

Vir Biotechnology Price Performance

Shares of Vir Biotechnology stock opened at $7.96 on Monday. Vir Biotechnology, Inc. has a 1-year low of $6.56 and a 1-year high of $13.09. The stock has a market cap of $1.10 billion, a P/E ratio of -2.03 and a beta of 0.46. The stock’s 50 day simple moving average is $7.90 and its 200-day simple moving average is $8.78.

Vir Biotechnology (NASDAQ:VIR) last issued its earnings results on Thursday, October 31st. The company reported ($1.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.05) by ($0.51). Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. The company had revenue of $2.38 million during the quarter, compared to analysts’ expectations of $5.54 million. During the same quarter in the previous year, the company earned ($1.22) earnings per share. The firm’s quarterly revenue was down 9.8% compared to the same quarter last year. As a group, research analysts expect that Vir Biotechnology, Inc. will post -3.36 EPS for the current fiscal year.

Vir Biotechnology Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).